Targeting a specific receptor to improve treatment for lung cancer
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer
This study is testing a new treatment that combines a drug called PBF-1129 with existing cancer therapies to see if it can help patients with advanced lung cancer fight their disease better by boosting their immune system.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11061370 on NIH RePORTER |
What this research studies
This research investigates the use of an A2B adenosine receptor antagonist, PBF-1129, in combination with immune checkpoint inhibitors for patients with metastatic non-small cell lung cancer (NSCLC). The study aims to enhance the effectiveness of current therapies by disrupting adenosine signaling, which tumors exploit to suppress immune responses. By conducting a phase Ib clinical trial, the researchers will evaluate whether this combination can improve patient outcomes compared to standard treatments. Patients participating in this trial may receive a novel treatment approach that could potentially enhance their immune response against the cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic non-small cell lung cancer who have not responded to standard immune checkpoint inhibitor therapies.
Not a fit: Patients with early-stage lung cancer or those who have not been diagnosed with non-small cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with metastatic non-small cell lung cancer who currently do not respond to existing therapies.
How similar studies have performed: Other research has shown promising results with similar approaches targeting adenosine signaling in cancer treatment, indicating potential for success in this study.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Carbone, David P. — Ohio State University
- Study coordinator: Carbone, David P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.